Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), sold 30,000 shares of common stock on October 10, 2025, for a total of $1.62 million. The shares were sold at prices ranging from $53.92 to $54.09. The transaction comes as the stock shows strong momentum, with a 15.75% gain in the past week and trading near its 52-week high of $58.40. According to InvestingPro, technical indicators suggest the stock is currently in overbought territory.
On the same day, Cheng also exercised options to acquire 30,000 shares of Akero Therapeutics common stock at an exercise price of $19.87, for a total value of $596,100.
Following these transactions, Cheng directly owns 526,114 shares of Akero Therapeutics.
The reported transactions were executed under a pre-arranged Rule 10b5-1 trading plan that Cheng adopted on August 16, 2024.
In other recent news, Novo Nordisk announced a definitive agreement to acquire Akero Therapeutics for up to $5.2 billion in cash. Akero shareholders will receive $54.00 per share in cash at closing, with an additional $6.00 per share contingent upon U.S. regulatory approval of Akero’s lead product candidate, efruxifermin (EFX), by June 30, 2031. Akero is set to present 96-week data from its Phase 2b studies of efruxifermin at the American Association for the Study of Liver Diseases annual meeting in November. In analyst updates, H.C. Wainwright initiated coverage on Akero with a Buy rating and a price target of $72.00, citing the potential of efruxifermin in reversing cirrhosis. Morgan Stanley has reiterated an Overweight rating for Akero, with an $84.00 price target, following Novo Nordisk’s decision to discontinue its own MASH treatment, zalfermin. Additionally, TD Cowen initiated coverage on Akero with a Buy rating and a $76.00 price target, highlighting the strong efficacy data of efruxifermin. These developments indicate a period of significant activity and interest in Akero’s therapeutic offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.